Frederick biologics manufacturing facility expansion
AstraZeneca, Frederick, Maryland
Frederick biologics manufacturing facility expansion in Frederick, Maryland is AstraZeneca’s plant for commercial biologics, including rare disease portfolio. Status: announced as of November 21, 2025. Primary source: governor.maryland.gov, checked November 12, 2026.
- Status
- Announced
- Announced investment
- Not stated
- Announced jobs
- 200
- Industry
- Pharmaceuticals
- Sheet
- MD-02
- Revised
- November 12, 2026
Status timeline
- Announcedgovernor.maryland.gov
Filled dots are confirmed by a company, state, SEC or federal source. Dashed dots come from news reports only. Investment and job figures are as announced, not achieved.
Plant facts
| Company | AstraZeneca |
|---|---|
| Plant | Frederick biologics manufacturing facility expansion |
| Location | Frederick, Maryland |
| Industry | Pharmaceuticals |
| Product | Commercial biologics, including rare disease portfolio |
| Announced investment | Not statedPart of a $2 billion Maryland investment covering Frederick and Gaithersburg; not split by site. Expected operational 2029 |
| Announced jobs | 200 |
| Last checked | November 12, 2026 |
No primary source we found states the announced investment, so we leave it blank rather than estimate.
Sources
- Governor Moore and AstraZeneca announce $2 billion investment to expand manufacturing in Maryland (state release, governor.maryland.gov, checked November 12, 2026)
Something changed? Send a correction with a link and we'll recheck it.